Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Englewood, New Jersey Clinical Trials

A listing of Englewood, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (10) clinical trials

Neoadjuvant Hiltonol (PolyICLC) for Prostate Cancer

This is a pilot dose escalation study of IT/IM Poly-ICLC in patients with high risk clinically localized prostate cancer. The dose and frequency of IT injections will be increased in successive cohorts to define a safe dose and schedule for further testing. Intratumoral + intramuscular poly-ICLC in patients with clinical ...

Phase

7.28 miles

Learn More »

A Study of Cetrelimab (JNJ-63723283) a Programmed Cell Death Receptor-1 (PD-1) Inhibitor Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

This study is of participants originally diagnosed with adenocarcinoma of the prostate who have now developed mCRPC and who have progressed on therapy with abiraterone acetate plus prednisone/prednisolone (AA-P), apalutamide, or enzalutamide. Participants with treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) assessed by the screening biopsy may be considered for this ...

Phase

7.29 miles

Learn More »

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Phase I dose escalation study with 177Lu-PSMA-617 using dose fractionation regimen will be performed in patients with documented progressive metastatic CRPC. The cumulative 177Lu dose [100 mCi (3.7 GBq) - 600 mCi (22.2 GBq)] will be escalated in up to 6 different dose levels (3 + 3 study design). Additional ...

Phase

8.75 miles

Learn More »

Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer

The proposed phase I clinical trial will investigate the safety and tolerability of 177Lu-CYT-500 and determine the optimal antibody mass and dose of 177Lu to be used for further study. The biodistribution and pharmacokinetics will also be assessed. Patients with histologically documented prostate cancer that is progressing following castration will ...

Phase

8.75 miles

Learn More »

Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

The purpose of the study is to find out the feasibility and effects of ultra-hypofractionated radiotherapy to the prostate and dominant lesion as definitive treatment for intermediate risk prostrate cancer.

Phase

8.95 miles

Learn More »

Phase I Trial of Apalutamide Plus Abiraterone Acetate Docetaxel and Prednisone in Patients With mCRPC

Subjects are enrolled in up to three 3-6-subject cohorts and are administered combination (apalutamide, abiraterone acetate and docetaxel plus prednisone) according to a dose-escalation schedule. The first dose of docetaxel infusion begins on Day 1 Cycle 1. Daily oral apalutamide, abiraterone acetate plus twice-daily oral prednisone begins on Day 1 ...

Phase

8.95 miles

Learn More »

Use of an Experimental Drug CC-115 With Enzalutamide in Men With Castration-Resistant Prostate Cancer

The main purpose of this study to define the good and/or bad effects of the combination of enzalutamide and CC-115 in patients with castration-resistant prostate cancer.

Phase

8.95 miles

Learn More »

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

This is a first in human, multinational, phase 1, open-label study of TAS3681 in patients with metastatic castration resistant prostate cancer (mCRPC)evaluating safety, tolerability, pharmacokinetics and preliminary antitumor activity in patients with mCRPC for which there is no standard therapy. Eligible patients will either be enrolled in the dose escalation ...

Phase

8.95 miles

Learn More »

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.

Phase

8.95 miles

Learn More »

Study to Evaluate the Safety Tolerability Pharmacokinetics and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate in Patients With Metastatic Castration Resistant Prostate Cancer

The study medication (BAY 2315497 Injection) is a thorium-227 labeled immuno-conjugate, specific for the prostate-specific membrane antigen (PSMA), which will be evaluated in patients with metastatic castration resistant prostate cancer. In this study, this investigational medication will be administered to patients for the first time. The primary objective of the ...

Phase

8.95 miles

Learn More »